Aripiprazole as a First-Line Antipsychotic Option

Introduction to Aripiprazole

The American Psychiatric Association recommends aripiprazole, olanzapine, and risperidone as first-line antipsychotic options for schizophrenia, with the choice guided by side-effect profiles and patient-specific factors 1
The 2025 INTEGRATE guidelines suggest that first-generation versus second-generation classifications should not guide drug selection, as these categories lack meaningful pharmacological or clinical distinctions 1
Initial antipsychotic choice should be based on side-effect profiles rather than arbitrary drug class distinctions 1

Aripiprazole functions as a D2 partial agonist, distinguishing it pharmacologically from olanzapine and risperidone (both D2 antagonists) 1
If a patient fails initial treatment with a D2 partial agonist like aripiprazole, switching to a D2 antagonist such as risperidone, olanzapine, or amisulpride is recommended to provide a different pharmacodynamic profile 1

Aripiprazole has a lower risk of metabolic side effects (weight gain, glucose/lipid abnormalities) compared to olanzapine 1
Aripiprazole causes less extrapyramidal symptoms (EPS) compared to risperidone, particularly at risperidone doses >6 mg/24h 2

For bipolar mania, aripiprazole is FDA-approved at 15-30 mg/day and represents an equivalent option to olanzapine or risperidone 3
For clozapine augmentation, aripiprazole can be added when significant positive symptoms persist after adequate clozapine trial 1
For persistent negative symptoms, aripiprazole is specifically recommended when switching antipsychotics due to its unique dopamine-serotonin stabilizing properties 1

Aripiprazole's activating profile (insomnia, agitation, akathisia) may be poorly tolerated in patients requiring sedation, where olanzapine or quetiapine would be preferable 2
Olanzapine requires metabolic monitoring and often concurrent metformin, making aripiprazole a metabolically safer alternative 1
Risperidone's dose-dependent EPS risk (particularly >6 mg/day) and prolactin elevation make aripiprazole advantageous for patients at risk for these effects 2
Assess treatment response at 4 weeks with therapeutic dosing and good adherence before considering switching 1